Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Pipeline Review, H1 2016

  • ID: 3746933
  • Report
  • Region: Global
  • 56 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Chrysalis Pharma SAS
  • Griffin Discoveries BV
  • Johnson & Johnson
  • OSE Pharma SA
  • Palau Pharma, S.A.
  • Sensorion S.A.
  • MORE
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Pipeline Review, H1 2016

Summary

‘Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Pipeline Review, H1 2016’, provides in depth analysis on Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted pipeline therapeutics.

The report provides comprehensive information on the Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105)
- The report reviews Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics and enlists all their major and minor projects
- The report assesses Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Chrysalis Pharma SAS
  • Griffin Discoveries BV
  • Johnson & Johnson
  • OSE Pharma SA
  • Palau Pharma, S.A.
  • Sensorion S.A.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) Overview

Therapeutics Development

Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Products under Development by Stage of Development

Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Products under Development by Therapy Area

Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Products under Development by Indication

Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Products under Development by Companies

Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Companies Involved in Therapeutics Development

Chrysalis Pharma SAS

Griffin Discoveries BV

Johnson & Johnson

OSE Pharma SA

Palau Pharma, S.A.

Sensorion S.A.

Ziarco Pharma Ltd

Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Drug Profiles

GD-134 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GD-136 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GD-48 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-28307474 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-28610244 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-40279486 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SENS-218 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Histamine H4 Receptor for Vestibular Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

toreforant tartrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tritoqualine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UR-63325 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZPL-3893787 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Dormant Projects

Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Discontinued Products

Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Featured News & Press Releases

Feb 22, 2016: Sensorion Presents SENS-218 Data at Association for Research in Otolaryngology Meeting

Feb 02, 2016: Phase 2a Psoriasis Study Initiated with Ziarco Lead Compound ZPL-389

Jan 06, 2016: Sensorion Receives Approval from the UK Drug Agency to Initiate Clinical Trial of SENS-218

Jun 10, 2015: Ziarco Initiates Phase 2a Clinical Trial of ZPL-389 in Atopic Dermatitis

Apr 23, 2015: Sensorion successfully completes the first part of the clinical trial on SENS-111, which aims to treat severe bouts of vertigo

Jun 18, 2014: Ziarco Secures £1.7M Grant from UK’s Technology Strategy Board to Support Phase 2a of ZPL-389 in Atopic Dermatitis

Jun 08, 2010: Palau Pharma Reports Positive First-In-Man Phase I Clinical Trial Results For Its Histamine H4 Receptor Antagonist UR-63325

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Chrysalis Pharma SAS, H1 2016

Pipeline by Griffin Discoveries BV, H1 2016

Pipeline by Johnson & Johnson, H1 2016

Pipeline by OSE Pharma SA, H1 2016

Pipeline by Palau Pharma, S.A., H1 2016

Pipeline by Sensorion S.A., H1 2016

Pipeline by Ziarco Pharma Ltd, H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Dormant Projects (Contd..2), H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Chrysalis Pharma SAS
  • Griffin Discoveries BV
  • Johnson & Johnson
  • OSE Pharma SA
  • Palau Pharma, S.A.
  • Sensorion S.A.
  • MORE
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies. Our latest report Histamine H4 Receptor – Pipeline Review, H1 2016, outlays comprehensive information on the Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) The histamine H4 receptor is a member of the G protein-coupled receptor super family. H4 receptors modulate eosinophil migration and selective recruitment of mast cells leading to amplification of histamine-mediated immune responses and eventually to chronic inflammation. H4 receptor involvement in dendritic cell activation and T cell differentiation documents its immunomodulatory function. The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 9 and 1 respectively.

Furthermore, this report also reviews key players involved in Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Chrysalis Pharma SAS
Griffin Discoveries BV
Johnson & Johnson
OSE Pharma SA
Palau Pharma, S.A.
Sensorion S.A.
Ziarco Pharma Ltd
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll